Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study
Nathan Fowler(Repligen (United States)), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Peter Martin(Northwestern University), Robert W. Chen, Ranjana H. Advani(Stanford Medicine), Jutta K. Neuenburg(Gladstone Institutes), Mark Knapp, Sumeet Bhatia, Sven de Vos(University of California, Los Angeles), Raul Mena, Ian W. Flinn(Tennessee Oncology), Samuel Suzuki(Theravance Biopharma (United States)), Darrin M. Beaupre(Pharmacyclics (United States))
Cited by 9
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k